We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Not even a whistle

22 April 2005 By Robert Cyran

The Swiss biotech has set aside 9% of the group s market capitalisation following the indictment of four executives on kickback charges. The unexpected size and suddenness of the charge reflect poorly on management s credibility.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)